Timothy E. Dribin, from the division of emergency medicine, at Cincinnati Children’s Hospital Medical Center.

International Consensus on Epinephrine Use, With Timothy E. Dribin, MD

Uncertainty around when patients should administer epinephrine for 

 in community settings prompted an international expert panel to develop consensus-based recommendations.

 The resulting report aims to reduce persistent variation in anaphylaxis action plans.

 spoke with first author Timothy E. Dribin, MD, from the division of emergency medicine, at Cincinnati Children’s Hospital Medical Center, on what clinical gap prompted this international consensus on epinephrine and EMS activation, and how this report addresses both underuse and overuse of epinephrine in community settings.

“The number one question that I get when patients leave our emergency departments, when we prescribe them an autoinjector, is: when should I administer epinephrine? What symptoms should I administer epinephrine for? It's a very complicated answer because there's no consensus on what symptoms warrant epinephrine and what symptoms do not warrant epinephrine,” Dribin said.

He continued by saying that different organizations have their own action plans. Recommendations differ from country to country.

“To address that gap, we said, ‘look, it'd be really helpful if we could have some international recommendations based on the views of an expert panel to try to resolve that variation and come up with consensus around…when…patients [should] administer epinephrine,’” Dribin said. “It is important to note, though, that in clinical practice, we always say if in doubt, patients and caregivers should just err on the side of giving epinephrine, given that it's a very, very safe medicine.”

Although early intramuscular epinephrine remains the first-line treatment for anaphylaxis, real-world studies suggest it is underused. Dribin noted that only approximately 21% of children and 7% of adults with anaphylaxis receive epinephrine before arriving at the emergency department. Delayed or absent epinephrine has been associated with worse outcomes, including increased hospitalization risk.

To address this variability, investigators convened a 34-member international panel from January 2024 through May 2025 and used a modified Delphi process to develop structured clinical scenarios reflecting differing severities and organ system involvement.

The panel categorized reactions across 4 organ systems: cutaneous or mucosal, respiratory, cardiovascular, and gastrointestinal. They generated 24 clinical scenarios representing isolated and combined system involvement, along with 9 candidate modifiers that could lower the threshold for epinephrine administration, such as comorbid asthma, and 12 potential EMS activation recommendations.

In phase 1 of the Delphi process, 21 of 24 scenarios reached consensus recommending epinephrine administration. Two scenarios reached consensus against epinephrine use, and one did not achieve consensus.

Agreement was strongest when reactions involved ≥ 2 organ systems. Isolated but severe respiratory symptoms, such as wheezing or dyspnea, and cardiovascular symptoms, including dizziness or hypotension, also generated high agreement for immediate epinephrine administration.

In contrast, isolated mild cutaneous symptoms, such as limited urticaria, or mild gastrointestinal symptoms, did not warrant epinephrine according to panel consensus. The single scenario that failed to reach consensus involved moderate mucocutaneous symptoms without other organ involvement. Dribin emphasized that this reflects real-world variability in clinician and caregiver risk tolerance.

The panel achieved consensus on 5 modifiers and 10 EMS activation recommendations. In phase 2, investigators embedded consensus modifiers into scenarios that initially did not recommend epinephrine or lacked consensus. Only 2 of 15 reassessed scenarios subsequently reached consensus for epinephrine administration, suggesting that modifiers did not broadly shift decision thresholds.

Dribin acknowledged that although underuse remains the larger public health concern, overuse carries implications. Administration of epinephrine typically prompts EMS activation or emergency department evaluation, which can result in healthcare expenditures, missed school or work, and patient anxiety.

For clinicians, Dribin advised contextual interpretation of the consensus statements, particularly in scenarios where agreement was not reached. He cautioned against viewing the recommendations as prescriptive mandates, noting that shared decision-making and individualized counseling remain central.

“Ultimately, what we are doing right now is we're trying to build a smartphone application that can incorporate these algorithms, so that in real time, patients and caregivers can receive prescriptive advice about whether to administer epinephrine,” Dribin said. “…it will also spur them to observe their symptoms and either re-dose epinephrine, or for those reactions where they didn't initially administer epinephrine, if their reactions were to get worse, it would make sure that they're checking their symptoms and then administering that device.”

Dribin TE, Sampson HA, Anagnostou A, et al. Epinephrine and emergency medical services activation recommendations during acute allergic reactions in community settings: International consensus report. 

Golden DBK, Wang J, Waserman S, et al. Anaphylaxis: A 2023 practice parameter update. 

Videos

Expert panel identifies high agreement for multi-organ involvement, but uncertainty remains in moderate isolated skin or mucosal symptoms.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Dry powder and soft mist inhalers in the long-acting muscarinic antagonist–long-acting β-agonist (LAMA–LABA) class were associated with modestly lower exacerbation risk in people with 

 (COPD) compared with a metered-dose inhaler (MDI) in a large US claims-based study published in 

“The inhalers we studied are the first line treatment for many patients with COPD, so it’s reassuring to see evidence that lower-emission inhalers may also be associated with slightly better clinical outcomes,” William Feldman, a pulmonologist and health services researcher at UCLA Health and the study’s senior author, wrote.

 “These findings highlight the opportunity to reduce healthcare-related emissions while potentially improving patient care.”

COPD affects more than 16 million US adults and remains a leading cause of hospitalization and death.

 Prevention of moderate and severe exacerbations is central to management, and dual bronchodilator therapy with LAMA–LABA combinations is recommended for many symptomatic patients.

 MDIs commonly use hydrofluoroalkane propellants, which have high global warming potential, whereas dry powder inhalers (DPIs) and soft mist inhalers (SMIs) do not require propellants and have substantially lower associated emissions.

The new study’s findings add comparative effectiveness data to ongoing discussions about inhaler selection in COPD, including consideration of environmental impact.

Feldman and colleagues conducted a retrospective, matched cohort study using commercial and Medicare Advantage claims from 2016 through 2025, including adults aged 40 years or older initiating a LAMA–LABA inhaler.¹ Three pairwise matched cohorts were constructed:

9,479 matched pairs receiving umeclidinium–vilanterol (DPI) vs glycopyrrolate–formoterol (MDI) (mean age, 68.9 years; standard deviation [SD], 9.0; 10,319 women, 54.4%; 8,636 men, 45.6%)

9,598 matched pairs receiving tiotropium–olodaterol (SMI) vs MDI (mean age, 69.2 years; SD, 8.7; 10,513 women, 54.8%; 8,680 men, 45.2%)

36,740 matched pairs receiving DPI vs SMI (mean age, 71.5 years; SD, 8.4; 39,429 women, 53.7%; 34,044 men, 46.3%)

The primary outcome was time to first moderate or severe COPD exacerbation. Safety outcomes included first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization.

Portela and colleagues found that compared with MDI, DPI was associated with a 14% lower hazard of a first moderate or severe exacerbation (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91), corresponding to a number needed to treat (NNT) of 17.¹ SMI was associated with a 6% lower hazard compared with the MDI (HR, 0.94; 95% CI, 0.89-1.00).¹

In a direct comparison between the 2 lower-emission devices, DPI was associated with a 3% lower hazard than tiotropium–olodaterol (HR, 0.97; 95% CI, 0.94-0.99), with an NNT of 100.¹ Absolute differences were modest across comparisons.

 Retrospective matched cohort analysis (2016–2025 claims data)

 Adults ≥40 years initiating LAMA–LABA therapy

 First moderate or severe COPD exacerbation

DPI vs MDI: HR 0.86 (95% CI, 0.81-0.91); NNT 17

DPI vs SMI: HR 0.97 (95% CI, 0.94-0.99); NNT 100

 Similar risks of MACE, UTI, pneumonia hospitalization

 DPIs and SMIs avoid high–global warming potential propellants

Safety outcomes were similar across all 3 cohorts, with no meaningful differences in risks of major adverse cardiovascular events, urinary tract infections, or pneumonia hospitalization.¹

Although randomized trials have established the efficacy of dual bronchodilators, head-to-head comparisons across inhaler platforms are limited.⁵ The present study suggests that, in routine practice, certain lower-emission inhalers may be associated with slightly fewer exacerbations without added safety risk.

However, as an observational analysis, the findings are subject to residual confounding. Claims data lack spirometry, symptom burden, and inhaler technique measures, and adherence patterns may differ by device. The modest hazard differences—particularly the 3% relative reduction between DPI and SMI—should be interpreted cautiously.

“This combination makes a strong case for using DPIs when possible,” Feldman said.

 “Although some patients may require MDIs, DPIs and SMIs are a safe and effective option for most patients with COPD.”

From an environmental standpoint, inhaler propellants contribute to healthcare-associated greenhouse gas emissions. When clinical outcomes are comparable, device selection may reasonably incorporate environmental considerations alongside patient ability, inspiratory flow capacity, and cost.

Altogether, the study supports consideration of DPIs or SMIs when appropriate from a clinical and patient-centered standpoint. While the magnitude of benefit was small, the absence of increased safety risk and the lower carbon footprint of these devices may inform shared decision-making in COPD management.

Feldman WB, et al. Comparative effectiveness and environmental impact of LAMA–LABA inhalers in chronic obstructive pulmonary disease. 

. Published online 2026. doi:10.1001/jamainternmed.2025.8087. 

https://doi.org/10.1001/jamainternmed.2025.8087

Dry powder inhalers show promise for COPD and the environment. News release. UCLA Health. February 23, 2026. 

https://www.uclahealth.org/news/release/dry-powder-inhalers-show-promise-copd-and-environment

Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease (COPD). Updated 2024. 

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD, 2024 Report. 

Articles

A large US claims-based matched cohort analysis comparing LAMA–LABA delivery platforms in COPD found modestly lower exacerbation risk with lower-emission devices. Dry powder inhalers (umeclidinium–vilanterol) reduced time to first moderate/severe exacerbation versus metered-dose inhalers (glycopyrrolate–formoterol) (HR 0.86; NNT 17), while soft mist inhalers (tiotropium–olodaterol) showed a smaller benefit (HR 0.94). Dry powder also slightly outperformed soft mist (HR 0.97; NNT 100). Safety outcomes were similar across platforms, supporting environmentally informed, patient-centered device selection.

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lower-Carbon LAMA–LABA Inhalers Linked to Modest Reductions in COPD Exacerbation Risk

Joshua Rothman, MD, MS, is a clinical assistant professor in the department of pediatrics and Medical Director of Informatics Academic Pediatrics at the University of California San Diego.

Could Falling Hepatitis B Vaccine Rates Reverse Decades of Progress?

For decades, universal newborn vaccination against hepatitis B has been a cornerstone of pediatric preventive care in the United States, widely regarded not only as protection against viral infection, but as a powerful tool in preventing chronic liver disease and liver cancer later in life.

 suggest that uptake of the birth dose may be slipping at a pivotal moment. Against a backdrop of evolving vaccine policy and shifting public discourse around immunization, these findings raise urgent questions about whether progress toward hepatitis B elimination could be at risk.

In discussing the findings from his research, Joshua Rothman, MD, MS, a clinical assistant professor in the department of pediatrics and Medical Director of Informatics Academic Pediatrics at the University of California San Diego, emphasized the critical importance of hepatitis B vaccination in infancy.

“Infants who are infected with hepatitis B in the first year of their life have up to a 90% risk of developing chronic hepatitis B, and that's associated with liver disease and cancer,” he explained. “Iif you think about it, the hepatitis B vaccine, especially in the early stages of life, is really like an anti-cancer vaccine.”

He goes on to explain how the rationale for administering the hepatitis B vaccine at birth is rooted in prevention of unexpected exposures. While maternal screening during pregnancy is standard, Rothman noted that false-negative maternal tests can occur. In addition, infants may be exposed through household members, caregivers, or delayed follow-up care. As such, the birth dose functions as a critical safety net, offering protection during a vulnerable period when the risk of progression to chronic infection is highest.

The study found that rates of the newborn hepatitis B vaccine declined by more than 10% over the past 2 years in the United States. Of note, this decline occurred before updated recommendations from the Advisory Committee on Immunization Practices (ACIP) in December 2025 and subsequent updated guidance from the Centers for Disease Control and Prevention (CDC) in January 2026. Rothman underscored that because the data predate these policy changes, vaccination rates may decline even further following the new guidance.

When considering possible drivers of the decrease, Rothman pointed to broader shifts in public discourse surrounding vaccines.

“I would say that coming out of the COVID-19 pandemic, there was a concern about messaging around the COVID vaccine, and then that conversation seemed to shift into childhood vaccinations in general,” he said.

While chronic hepatitis B rates in the United States have been declining for years, in large part due to vaccination efforts, Rothman cautioned that sustained declines in vaccination coverage could halt this progress or even reverse it. He says a reduction in early-life immunization may lead to an increase in pediatric infections, with long-term consequences that include chronic liver disease and liver cancer decades later.

Despite growing safety concerns among some parents, Rothman stressed that the hepatitis B vaccine has decades of evidence supporting its safety and efficacy. For pediatricians and healthcare providers, he said, the goal remains clear: eliminate hepatitis B, both nationally and globally. Until that goal is achieved, he emphasized the need for continued vigilance in counseling families about the importance of early, evidence-based protection.

Editors’ Note: Rothman reports no relevant disclosures.

Rothman JM, Kwan B, Longhurst CA, Jena AB. US Newborn Hepatitis B Virus Vaccination Rates. JAMA. Published online February 23, 2026. doi:10.1001/jama.2026.0866

Brooks A. CDC Changes Infant Hepatitis B Vaccine Recommendation. HCPLive. December 5, 2025. Accessed February 25, 2026. 

https://www.hcplive.com/view/cdc-changes-infant-hepatitis-b-vaccine-recommendation

New data show a >10% drop in newborn hepatitis B vaccination, raising concern for rising chronic infection and future liver cancer risk.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Declining Hepatitis B Birth Dose Rates and the Risk to Long-Term Liver Health, With Joshua Rothman, MD, MS

The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, with Jennifer Hsiao, MD

, host Mona Shahriari, MD, associate clinical professor of dermatology at Yale School of Medicine, welcomes Jennifer Hsiao, MD, a dermatologist and clinical associate professor of clinical dermatology at Keck Medicine of the University of Southern California (USC), for a thoughtful discussion on leadership, visibility, and building a meaningful academic career in dermatology.

The pair discuss the invisible labor of love faced by female physicians, particularly mothers. They explore the mental checklists, calendar management, and the constant juggling of professional and personal responsibilities. Hsiao shares her experience as a dermatologist and mother of two, highlighting the challenges of maintaining work-life balance and the societal expectations placed on mothers. They emphasize the importance of setting boundaries and the need for shared responsibilities at home.

The conversation centers on the evolving role of women in academic medicine and the unique pressures that come with balancing clinical excellence, scholarship, and personal fulfillment. Hsiao reflects on her path into dermatology, emphasizing that career trajectories are rarely linear. Rather than following a rigid roadmap, she describes making intentional decisions rooted in mentorship, curiosity, and alignment with her long-term values.

A key theme throughout the episode is the importance of visibility, particularly for women physicians navigating leadership spaces. Another focal point of the discussion is redefining success. Hsiao challenges the notion that academic achievement must come at the expense of personal well-being. Instead, she encourages physicians to ensure that their work aligns with what brings them fulfillment, whether that be research, teaching, clinical care, or leadership.

Throughout the episode, Shahriari and Hsiao acknowledge that while structural barriers still exist, there is increasing space for women to lead authentically and collaboratively. They emphasized the importance of advocating for themselves in modern society. The conversation concludes with reflections on the evolving roles of women in medicine and the need for grace and self-compassion.

Editor’s note: This summary was edited with the help of AI tools.

This February episode of The Medical Sisterhood highlights key points on juggling work as a clinician and work as a mother.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, With Jennifer Hsiao, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

Announced by parent company Eton Pharmaceuticals on February X, 2026, the 

 has approved ET-600 to treat central diabetes insipidus among pediatric patients.

ET-600, now under the label Desmoda, is the first and only FDA-approved oral liquid formulation of desmopressin. It will be supplied as a ready-to-use oral solution of 0.05 mg/mL that does not require tablet splitting, crushing, refrigeration, mixing, or shaking.

“In central diabetes insipidus, effective long-term management depends on accurately matching desmopressin dosing to each patient’s diurnal pattern of water balance,” Sean Brynjelsen, chief executive officer of Eton Pharmaceuticals, said in a statement. “Historically, clinicians have primarily relied on formulations that were not designed for fine dose adjustments or had other administration issues, and both clinicians and families often had to rely on workarounds. Desmoda introduces a liquid solution designed to deliver individualized dosing precision and consistency for patients across the age spectrum.”

 is a rare, complex disease wherein large volumes of dilute urine are excreted due to arginine-vasopressin deficiency (AVP-D). Its causes can be genetic, congenital, inflammatory, neoplastic, and traumatic, but mainly involve conditions arising from the hypothalamus.

Early diagnosis and treatment are crucial for pediatric patients in particular, given the disease’s potential for central nervous system damage and the risk of dissemination of germ cell tumor. Additionally, the disease can progress into Langerhans Cell Histiocytosis and additional pituitary defects.

Among the challenges presented by the disease is the differential diagnosis between central diabetes insipidus presenting with polyuria and polydipsia. This process requires a detailed medical history, biochemical approach, physical examination, imaging studies, and potentially histological confirmation. Pituitary stalk size is variable and can change depending on the underlying condition, and other brain areas or organs can become involved during follow-up.

Desmopressin is a synthetic vasopressin analog first approved in 1978 to manage diabetes insipidus, as well as hemophilia A and von Willebrand’s disease. ET-600 is the first oral liquid formulation of desmopressin. Eton Pharmaceuticals has received a patent for the formulation extending to 2044, with an additional patent under review.

The FDA’s decision was based on results from a bioequivalence study completed in March of 2025. Investigators from Eton enrolled 75 patients, who were then randomly assigned to receive the test and reference drug in an open-label, balanced, randomized, single-dose, 3-treatment, 3-sequence, 3-period, 3-way crossover oral bioequivalence study.

Ultimately, ET-600 displayed full pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. Following this, Eton submitted its first New Drug Application (NDA) for ET-600 to the FDA on July 8, 2025.

“Central diabetes insipidus requires careful, individualized management, where dosing precision and flexibility truly matter. Having a liquid formulation of desmopressin has the potential to meaningfully support how we initiate and manage therapy,” Lewis Blevins, director of the California Center for Pituitary Disorders and professor of medicine and neurological surgery at the University of California, San Francisco, said in a statement. “It’s encouraging to see innovation that directly addresses real-world challenges faced by clinicians and families and gives greater confidence when tailoring treatment across age groups.”

Eton Pharmaceuticals. Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA (desmopressin acetate) Oral Solution. February 25, 2026. Accessed February 25, 2026. 

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-desmodatm

Patti G, Ibba A, Morana G, et al. Central diabetes insipidus in children: Diagnosis and management. 

Eton Pharmaceuticals. Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution). July 8, 2025. Accessed February 24, 2026. 

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-acceptance-new-drug-1

Eton Pharmaceuticals. Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600. March 14, 2025. Accessed February 24, 2026. 

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-positive-pivotal-clinical-study

Eton Pharmaceuticals’ ET-600 (Desmoda) received FDA approval for pediatric central diabetes insipidus as the first oral liquid desmopressin formulation. The ready-to-use 0.05 mg/mL solution is designed to avoid tablet manipulation and other administration barriers, supporting finer dose titration aligned with diurnal water-balance needs. Central diabetes insipidus reflects arginine-vasopressin deficiency with heterogeneous etiologies and clinically demanding diagnostic workups, especially in children given CNS and multisystem risks. Approval was supported by a 75-subject crossover bioequivalence study demonstrating pharmacokinetic equivalence to the reference product.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA News

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

Mary K Roberts, PhD is a Post Doctoral Researcher at the Leverhulme Centre for Demographic Science at the University of Oxford.

Willingness to pursue living kidney donation is shaped by relationships, health, and a multidisciplinary approach, not just finances.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Living Donor Donation Works When Relationships Matter With Mary Roberts, PhD

Mark Creager, MD, is the director emeritus of the Heart and Vascular Center at Dartmouth University.

Creager discusses the accomplishments of the ACC and AHA’s joint PE clinical practice guideline while continuing to look to the future of the disease.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Strategic Alliance Partnership

New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD

Andres Hurtado-Lorenzo, PhD, is VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation.

Hurtado-Lorenzo discusses trial data showing time-restricted feeding in Crohn’s disease results in weight loss, symptom improvement, and microbiome changes.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

New Evidence on Meal Timing and Crohn’s Disease Outcomes, With Andres Hurtado-Lorenzo, PhD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Vanda Pharmaceuticals announced the FDA's acceptance of imsidolimab's Biologics License Application for the treatment of GPP.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

FDA Accepts BLA for Imsidolimab as Generalized Pustular Psoriasis Treatment

Matthew Jolley, MD, is the Topolewski Endowed Chair in Pediatric Cardiology at Children’s Hospital of Philadelphia.

Jolley discusses the team’s combination of volume rendering and cardiac MRI-based valve evaluation to provide 4D models of the heart and blood flow.

New Cardiac Imaging Method Directly Visualizes Pediatric Heart Defects, With Matthew Jolley, MD

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Systematic review identifies patient and clinician barriers to obesity management before kidney transplantation, with Adrian Brown, PhD.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Barriers to Obesity Management in Kidney Failure Before Transplantation

Mauro Cancian, MD, PhD, head of the allergy division at the University of Padua.

Updated HAE guidelines support early self-treatment; Cancian discuss transitioning patients from injectable on-demand therapy to oral sebetralstat after KONFIDENT data.

Transitioning to Oral On-Demand HAE Therapy, With Mauro Cancian, MD, PhD

Rare kidney diseases are hard to detect early, but precision therapies and updated guidelines offer new ways to improve patient outcomes.


RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

Rare Kidney Disease: Advances in Early Detection, Precision Therapies, and Clinical Practice Shifts With Swati Arora, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA

Susan Taylor, MD, a professor and vice chair for Diversity, Equity, and Inclusion at the Perelman School of Medicine. 

This new February episode of the Skin of Color Savvy podcast highlights why 2026 may be the year of skin health equity in the dermatology field.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Latest News

International Consensus on Epinephrine Use, With Timothy E. Dribin, MD

Lower-Carbon LAMA–LABA Inhalers Linked to Modest Reductions in COPD Exacerbation Risk

Declining Hepatitis B Birth Dose Rates and the Risk to Long-Term Liver Health, With Joshua Rothman, MD, MS

The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, With Jennifer Hsiao, MD

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus